Inactive Instrument

Nova Pharma Solutions

NPS

MYL03006O003

Nova Pharma Solutions Berhad Announces Resignation of Tan Hong Eng as Executive Director

May 01, 2019

Nova Pharma Solutions Berhad announced resignation of Miss Tan Hong Eng as Executive Director due to other personal commitment. Date of change is 01 May 2019.

Latest news about Nova Pharma Solutions

Nova Pharma Solutions Berhad Announces Interim Single-Tier Dividend for the Financial Year Ending 31 December 2023, Payable on 15 September 2023	23-08-17	CI
Nova Pharma Solutions' Profit, Revenue Rise in H1	23-08-16	MT
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-15	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-20	CI
Nova Pharma Solutions Berhad Proposes Interim Single-Tier Dividend for the Financial Year Ending 31 December 2022	22-08-23	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
67,054,279 Ordinary Shares of Nova Pharma Solutions Berhad are subject to a Lock-Up Agreement Ending on 9-MAR-2022.	22-03-08	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-23	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
Nova Pharma Solutions Berhad entered into an agreement to acquire remaining 49% stake in NOVA HITECH SOLUTIONS SDN. BHD from ACARA JUARA SDN BHD for MYR 0.05 million.	20-10-29	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-07	CI
Nova Pharma Solutions Berhad Appoints Mr. Ng Tik Hwa as Independent and Non Executive Director	20-07-01	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-21	CI
Nova Pharma Solutions Berhad Announces Single-Tier Interim Dividend for the Financial Year Ending 31 December 2019, Payment Date of 17 Jan. 2020	19-12-24	CI
Nova Pharma Solutions Berhad Approves Interim Single- Tier Dividend for the Financial Year Ending 31 December 2019	19-12-05	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-06	CI
Nova Pharma Solutions Berhad Announces Final Single Tier Dividend for the Financial Year Ended 31 December 2018, Payable on 08 August 2019	19-06-27	CI
Nova Pharma Solutions Berhad Announces Incorporation of Nova Incorporation of Hitech Solutions Sdn Bhd	19-06-12	CI
Nova Pharma Solutions Berhad Announces Joint Venture Cum Shareholders Agreement with Acara Juara Sdn Bhd	19-05-26	CI
Nova Pharma Solutions Berhad Proposes Final Single Tier Dividend, Payable on 08 August 2019	19-05-20	CI
Nova Pharma Solutions Berhad Announces Resignation of Tan Hong Eng as Executive Director	19-05-01	CI
67,030,228 Ordinary Shares of Nova Pharma Solutions Berhad are subject to a Lock-Up Agreement Ending on 9-MAR-2019.	19-03-08	CI
NOVA PHARMA SOLUTIONS BERHAD Recommends Final Single-Tier Dividend for the Financial Year Ended December 31, 2018	19-02-20	CI
Nova Pharma Solutions Berhad Reports Earnings Results for the Full Year Ended December 31, 2018	19-02-20	CI
Nova Pharma Solutions Berhad Announces Single-Tier Interim Dividend for the Year Ending 31 December 2018, Payable on 18 January 2019	18-12-12	CI

Nova Pharma Solutions Berhad is a Malaysia-based company, which is engaged in the business of provision of technical documentation, validation, and project execution in the pharmaceutical and biological industries. It operates through four segments: Design, Post Design, engineering, procurement, construction, and commissioning (EPCC) and Other Support. The Design segment comprise conceptual designs which include user requirement specification, capacity analysis and process scheduling with detailed costing, list of deliverables, details specification of various equipmentâs. The Post Design segment comprise tendering and procurement support as well as construction management of plant. The EPCC segment comprise of works and services pertaining to engineering, procurement, construction, and commissioning for advanced technology facilities. The Other Support segment comprise of services to assist customer in the manufacturing practice document review and gap analysis and assessment.

Sector

Construction & Engineering

Calendar

2024-08-20 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Construction & Engineering

	1st Jan change	Capi.
VINCI	+1.67%	71.03B
LARSEN & TOUBRO LIMITED	-7.35%	53.83B
QUANTA SERVICES, INC.	+25.80%	39.74B
CHINA STATE CONSTRUCTION ENGINEERING CORPORATION LIMITED	+13.93%	31.57B
FERROVIAL SE	+4.72%	27.28B
CHINA RAILWAY GROUP LIMITED	+17.96%	21.32B
EMCOR GROUP, INC.	+76.52%	17.87B
CHINA COMMUNICATIONS CONSTRUCTION COMPANY LIMITED	+38.79%	17.66B
CHINA RAILWAY CONSTRUCTION CORPORATION LIMITED	+14.98%	15.39B

Other Construction & Engineering